Neoplasms Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Sample Collection and Tracking for the Developmental Therapeutics Clinic
Recruiting
  • Neoplasms
  • Lymphoma
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-04-07
    Apr 7, 2022
    G
    Phase 1 First Time in Human (FTIH), Open Label Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
    Recruiting
    • Neoplasms
    • Houston, Texas
    • +9 more
    2022-04-07
    Apr 7, 2022
    N
    5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
    Recruiting
    • Neoplasms
    • Solid Tumors
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-04-07
    Apr 7, 2022
    C
    THrombo-Embolic Event in Onco-hematology
    Recruiting
    • Neoplasms
    • +2 more
    • Blood sample analysis
    • Nice, France
      Centre Antoine Lacassagne
    2022-04-07
    Apr 7, 2022
    N
    Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
    Suspended
    • Neoplasms
    • Solid Tumors
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2022-04-07
    Apr 7, 2022
    N
    Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain
    Enrolling by invitation
    • Cancer
    • +2 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      2022-04-07
      Apr 7, 2022
      N
      Mobile Sensor Technologies to Assess General Symptomology of People With Cancer
      Enrolling by invitation
      • Neoplasms
      • +4 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        2022-04-07
        Apr 7, 2022
        N
        M7824 Related Adverse Effects in Adults With Cancer
        Active, not recruiting
        • Neoplasms
        • Skin Neoplasms
          • Bethesda, Maryland
            National Cancer Institute (NCI)
          2022-04-07
          Apr 7, 2022
          N
          Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
          Recruiting
          • Neoplasms
          • +2 more
          • Bortezomib plus Clofarabine
          • Bethesda, Maryland
            National Institutes of Health Clinical Center, 9000 Rockville Pi
          2022-04-07
          Apr 7, 2022
          N
          Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
          Recruiting
          • Neoplasms
          • Nilotinib and Paclitaxel
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          2022-04-07
          Apr 7, 2022
          N
          Clinical and Genetic Studies of Li-Fraumeni Syndrome
          Recruiting
          • Li-Fraumeni Syndrome
          • +2 more
            • Bethesda, Maryland
            • +1 more
            2022-04-07
            Apr 7, 2022
            N
            A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas - 2017
            Completed
            • Neoplasms
            • Lymphoma
            • Bethesda, Maryland
              National Institutes of Health Clinical Center, 9000 Rockville Pi
            2022-04-07
            Apr 7, 2022
            N
            Data Collection, Clinical Care and Interventions in CCR, NCI
            Enrolling by invitation
            • Neoplasms
            • Cancer
              • Bethesda, Maryland
                National Institutes of Health Clinical Center, 9000 Rockville Pi
              2022-04-07
              Apr 7, 2022
              N
              FdCyd and THU for Advanced Solid Tumors - 2020
              Completed
              • Neoplasms
              • FdCyd + THU
              • Davis, California
              • +3 more
              2022-04-07
              Apr 7, 2022
              N
              Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
              Recruiting
              • Neoplasms
              • +2 more
                • Bethesda, Maryland
                  National Institutes of Health Clinical Center, 9000 Rockville Pi
                2022-04-07
                Apr 7, 2022
                B
                SUPR-3D: Simple Unplanned Palliative Radiotherapy Versus 3D Conformal Radiotherapy for Patients With Bone Metastases
                Recruiting
                • Neoplasm Metastasis
                • +3 more
                • SUPR
                • VMAT
                • Prince George, British Columbia, Canada
                • +4 more
                2022-04-06
                Apr 6, 2022
                T
                Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
                Recruiting
                • Neoplasms
                • Dostarlimab
                • Birmingham, Alabama
                • +105 more
                2022-03-29
                Mar 29, 2022
                B
                A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
                Recruiting
                • Neoplasms
                • San Antonio, Texas
                • +3 more
                2022-04-06
                Apr 6, 2022
                B
                Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
                Recruiting
                • Lung Neoplasm Malignant
                • +18 more
                • Fairfax, Virginia
                  New Experimental Therapeutics of Virginia (NEXT Oncology)
                2022-03-29
                Mar 29, 2022
                B
                A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab)
                Recruiting
                • Neoplasms
                • BI 907828
                • +2 more
                • New Haven, Connecticut
                • +3 more
                2022-04-06
                Apr 6, 2022
                B
                This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
                Active, not recruiting
                • Neoplasms
                • Carcinoma, Non-Small-Cell Lung
                • BI 754111
                • BI 754091
                • Miami, Florida
                • +14 more
                2022-04-06
                Apr 6, 2022
                L
                PC001- A Study to Evaluate the Usability of PointCheck
                Recruiting
                • Neoplasms
                • Neutropenia
                • PointCheck
                • Boston, Massachusetts
                  Boston Medical Center
                2022-04-06
                Apr 6, 2022
                G
                Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma - 2022
                Completed
                • Neoplasms
                • letetresgene autoleucel (GSK3377794)
                • +2 more
                • Tampa, Florida
                • +5 more
                2022-04-04
                Apr 4, 2022
                S
                A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
                Recruiting
                • Neoplasms
                • Indianapolis, Indiana
                • +4 more
                2022-04-04
                Apr 4, 2022
                B
                This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.
                Active, not recruiting
                • Neoplasms
                • Breast Neoplasms
                • Santa Monica, California
                • +29 more
                2022-04-05
                Apr 5, 2022